Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS).

Trial Profile

Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Sirolimus (Primary) ; Zotarolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms DIRECT-II
  • Sponsors Svelte Medical Systems
  • Most Recent Events

    • 25 Mar 2014 Planned End Date changed from 1 Jun 2018 to 1 May 2019 as reported by ClinicalTrail.gov record.
    • 14 Nov 2013 Status changed from recruiting to active, no longer recruiting, according to a Svelte Medical Systems media release. The final patient has been enrolled.
    • 07 Feb 2013 New source identified and integrated (ClinicalTrials.gov).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top